J. P. Nadda, today released the Indian Pharmacopoeia 2026 (IP 2026) - the 10th edition of India’s official book of drug standards at Dr. Ambedkar International Centre, New Delhi, marking a significant milestone in India’s ongoing efforts to strengthen the quality, safety, and efficacy of medicines.
Releasing the new edition, Shri Nadda highlighted that the Indian Pharmacopoeia serves as the official book of standards for drugs in the country and is a cornerstone of India’s regulatory framework for pharmaceuticals. He stated that the 10th edition reflects scientific advancements, global best practices, and India’s growing leadership in pharmaceutical manufacturing and regulation.
He also highlighted that Indian Pharmacopoeia 2026 incorporated 121 new monographs, increasing the total number of monographs to 3,340. He further noted that coverage has been significantly strengthened across key therapeutic categories, including anti-tubercular, anti-diabetic and anti-cancer medicines, as well as iron supplements, thereby ensuring more comprehensive standardisation of medicines used under various National Health Programmes.
Referring to pharmacovigilance, Union Health minister stated that, ‘In recent years, the Indian Pharmacopoeia standards have also gained international acceptance as it has become a focused agenda under the health diplomacy of the Government of India. He also noted that, Indian Pharmacopoeia is now recognised in 19 countries of the global south.
Copyright © 2017 Indian Grapevine a unit of Integrated Media Enterprises
